[低胆固醇和极低胆固醇水平:我们需要知道什么]。

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Stefania Angela Di Fusco, Massimo Leggio, Vered Gil Ad, Simona Giubilato, Stefano Aquilani, Federico Nardi, Massimo Grimaldi, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Imperoli, Furio Colivicchi
{"title":"[低胆固醇和极低胆固醇水平:我们需要知道什么]。","authors":"Stefania Angela Di Fusco, Massimo Leggio, Vered Gil Ad, Simona Giubilato, Stefano Aquilani, Federico Nardi, Massimo Grimaldi, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Imperoli, Furio Colivicchi","doi":"10.1714/4318.43039","DOIUrl":null,"url":null,"abstract":"<p><p>Due to the growing evidence of clinical benefits conferred by the reduction of low-density lipoprotein cholesterol (LDL-C) levels, the availability of multiple effective lipid-lowering agents, and guideline recommendations, clinicians not infrequently have to manage patients with low or very low LDL-C levels. In clinical practice it is essential to consider that, when LDL-C plasma concentrations are low, the Friedewald formula commonly used for LDL-C level calculation is less accurate, hence risk assessment should be integrated by using different methods for LDL-C level quantification and other parameters, such as non-high-density lipoprotein cholesterol and, where possible, apolipoprotein B, should be measured. As regards the clinical impact of low LDL-C levels, genetically determined hypocholesterolemia forms provide reassuring data on the effects of this condition in the long term, except for the forms with extremely low or undetectable LDL-C levels. Evidence from clinical studies that used highly effective lipid-lowering drugs, such as proprotein convertase subtilisin/kexin type 9 inhibitors, goes in the same direction. In these studies, the incidence of non-cardiovascular adverse events in patients who reached very low LDL-C levels was similar to that in the placebo arm. Overall, the fear of adverse effects should not deter intensive lipid-lowering treatment when indicated to reduce the risk of cardiovascular events.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"25 9","pages":"650-659"},"PeriodicalIF":0.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Low and very low cholesterol levels: what we need to know].\",\"authors\":\"Stefania Angela Di Fusco, Massimo Leggio, Vered Gil Ad, Simona Giubilato, Stefano Aquilani, Federico Nardi, Massimo Grimaldi, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Imperoli, Furio Colivicchi\",\"doi\":\"10.1714/4318.43039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Due to the growing evidence of clinical benefits conferred by the reduction of low-density lipoprotein cholesterol (LDL-C) levels, the availability of multiple effective lipid-lowering agents, and guideline recommendations, clinicians not infrequently have to manage patients with low or very low LDL-C levels. In clinical practice it is essential to consider that, when LDL-C plasma concentrations are low, the Friedewald formula commonly used for LDL-C level calculation is less accurate, hence risk assessment should be integrated by using different methods for LDL-C level quantification and other parameters, such as non-high-density lipoprotein cholesterol and, where possible, apolipoprotein B, should be measured. As regards the clinical impact of low LDL-C levels, genetically determined hypocholesterolemia forms provide reassuring data on the effects of this condition in the long term, except for the forms with extremely low or undetectable LDL-C levels. Evidence from clinical studies that used highly effective lipid-lowering drugs, such as proprotein convertase subtilisin/kexin type 9 inhibitors, goes in the same direction. In these studies, the incidence of non-cardiovascular adverse events in patients who reached very low LDL-C levels was similar to that in the placebo arm. Overall, the fear of adverse effects should not deter intensive lipid-lowering treatment when indicated to reduce the risk of cardiovascular events.</p>\",\"PeriodicalId\":12510,\"journal\":{\"name\":\"Giornale italiano di cardiologia\",\"volume\":\"25 9\",\"pages\":\"650-659\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Giornale italiano di cardiologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1714/4318.43039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4318.43039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

由于越来越多的证据表明降低低密度脂蛋白胆固醇(LDL-C)水平可带来临床益处、多种有效降脂药物的可用性以及指南建议,临床医生经常需要管理低密度脂蛋白胆固醇(LDL-C)水平较低或非常低的患者。在临床实践中,必须考虑到当低密度脂蛋白胆固醇(LDL-C)血浆浓度较低时,通常用于计算 LDL-C 水平的弗里德瓦尔德公式的准确性较低,因此应采用不同的 LDL-C 水平定量方法综合进行风险评估,并测量其他参数,如非高流脂蛋白胆固醇,以及在可能的情况下测量脂蛋白 B。至于低 LDL-C 水平的临床影响,除了极低或检测不到 LDL-C 水平的低胆固醇血症外,由基因决定的低胆固醇血症都提供了令人放心的长期影响数据。使用高效降脂药物(如 Prorotein convertase subtilisin/kexin type 9 抑制剂)进行的临床研究也提供了相同的证据。在这些研究中,达到极低 LDL-C 水平的患者非心血管不良事件的发生率与安慰剂组相似。总之,在有降低心血管事件风险的指征时,对不良反应的恐惧不应阻碍强化降脂治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Low and very low cholesterol levels: what we need to know].

Due to the growing evidence of clinical benefits conferred by the reduction of low-density lipoprotein cholesterol (LDL-C) levels, the availability of multiple effective lipid-lowering agents, and guideline recommendations, clinicians not infrequently have to manage patients with low or very low LDL-C levels. In clinical practice it is essential to consider that, when LDL-C plasma concentrations are low, the Friedewald formula commonly used for LDL-C level calculation is less accurate, hence risk assessment should be integrated by using different methods for LDL-C level quantification and other parameters, such as non-high-density lipoprotein cholesterol and, where possible, apolipoprotein B, should be measured. As regards the clinical impact of low LDL-C levels, genetically determined hypocholesterolemia forms provide reassuring data on the effects of this condition in the long term, except for the forms with extremely low or undetectable LDL-C levels. Evidence from clinical studies that used highly effective lipid-lowering drugs, such as proprotein convertase subtilisin/kexin type 9 inhibitors, goes in the same direction. In these studies, the incidence of non-cardiovascular adverse events in patients who reached very low LDL-C levels was similar to that in the placebo arm. Overall, the fear of adverse effects should not deter intensive lipid-lowering treatment when indicated to reduce the risk of cardiovascular events.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Giornale italiano di cardiologia
Giornale italiano di cardiologia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信